SARS-CoV-2 Spike Protein (CR3022) Human IgG1 Monoclonal Antibody#37475,Cell Signaling Technology (CST),37475
SARS-CoV-2 Spike Protein (CR3022) Human IgG1 Monoclonal Antibody recognizes an epitope in the receptor binding domains (RBDs) of SARS-CoV-2 and SARS-CoV spike proteins. This antibody has been reported to bind to both wild-type and P462L-mutant versions of the SARS spike protein. The epitope is only accessible in the "open" conformation of the spike protein (10,11).
Host
Human
Reactivity
Virus
Platform ID
BAB131381258
Cell Signaling Technology (CST)
Contact
Tel: 877-616-2355,978-867-2388
Fax: 877-616-2355
Email:
Specifications
Scientific Background
The cause of the COVID-19 pandemic is a novel and highly pathogenic coronavirus, termed SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). SARS-CoV-2 is a member of the Coronaviridae family of viruses (1). The genome of SARS-CoV-2 is similar to other coronaviruses, and is comprised of four key structural proteins: S, the spike protein, E, the envelope protein, M, the membrane protein, and N, the nucleocapsid protein (2). Coronavirus spike proteins are class I fusion proteins and harbor an ectodomain, a transmembrane domain, and an intracellular tail (3,4). The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases at S1/S2 and S2’ sites. S1 and S2 subunits remain associated after cleavage and assemble into crown-like homotrimers (2,4). In humans, both SARS-CoV and SARS-CoV-2 spike proteins utilize the angiotensin-converting enzyme 2 (ACE2) protein as a receptor for cellular entry (5-7). Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors (8,9).Zhou, P. et al. (2020)Nature579, 270-3.Tortorici, M.A. and Veesler, D. (2019)Adv Virus Res105, 93-116.Li, F. et al. (2006)J Virol80, 6794-800.Li, F. (2016)Annu Rev Virol3, 237-61.Shang, J. et al. (2020)Nature581, 221-4.Wrapp, D. et al. (2020)Science367, 1260-3.Yan, R. et al. (2020)Science367, 1444-8.Yuan, Y. et al. (2017)Nat Commun8, 15092.Amanat, F. and Krammer, F. (2020)Immunity52, 583-9.ter Meulen, J. et al. (2006)PLoS Med3, e237.Tian, X. et al. (2020)Emerg Microbes Infect9, 382-5.van den Brink, E.N. et al. (2005)J Virol79, 1635-44.Alternate Names2019-nCoV surface glycoprotein; Peplomer protein; S glycoprotein; SARS-CoV-2 spike protein; spike glycoprotein; SPIKE_SARS2; surface glycoprotein
Synonyms
2019-nCoV surface glycoprotein; Peplomer protein; S glycoprotein; SARS-CoV-2 spike protein; spike glycoprotein; SPIKE_SARS2; surface glycoprotein
Category Paths
Please provide the required information below so that we can quickly source your products.
